Clinical Research Directory
Browse clinical research sites, groups, and studies.
Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Sponsor: XueMei Guo
Summary
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
Official title: Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-12-10
Completion Date
2027-11-09
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
Orlistat 120 mg
Oral capsule, taken after meals, 120 mg three times daily (tid) for 24 weeks.
Allopurinol 100 up to 600mg/day
Standard urate-lowering therapy (e.g., allopurinol or febuxostat), with doses adjusted based on serum uric acid levels and liver/kidney function.
Febuxostat 40mg Tab
Standard urate-lowering therapy (e.g., allopurinol or febuxostat), with doses adjusted based on serum uric acid levels and liver/kidney function.
Locations (1)
General Hospital of Northern Theater Command, PLA
Shenyang, Liaoning, China